How often should TRT patients actually get bloodwork done?

What did @marekhealth actually say?

The creator recommends getting bloodwork every three to six months while on TRT, with more frequent testing in the first 60 days. Specifically, they flag testosterone (total and free), estrogen, DHT, SHBG, prolactin, CBC with hematocrit, liver enzymes, kidney markers, and PSA as the relevant panels. They also mention monthly testing throughout a decade-plus competitive career as personal evidence for why frequent monitoring matters.

This is a fairly comprehensive list, and the framing, that early-phase monitoring is more aggressive than maintenance monitoring, is clinically reasonable. The creator is not selling a specific protocol here, which is worth noting. They're describing a general surveillance approach, not prescribing doses or specific interventions.

Does the science back this up?

Mostly, yes, but with some nuance. The Endocrine Society's 2018 clinical practice guidelines recommend checking testosterone levels 3-6 months after starting TRT, then annually if stable. That aligns with the creator's maintenance recommendation. The American Urological Association similarly advises hematocrit monitoring at 3-6 months initially, then annually. The 30-60 day early check the creator recommends is not formally specified in most guidelines, but it's defensible clinically, particularly for dose titration.

On hematocrit specifically, the risk is real. Bachman et al. (2014, Journal of Clinical Endocrinology and Metabolism) found erythrocytosis rates exceeding 20% in some TRT cohorts, particularly with injectable testosterone. Monitoring hemoglobin and hematocrit early is not overcautious, it's standard practice. PSA monitoring is also guideline-supported, per Morgentaler et al. (2011, Journal of Urology), though the magnitude of TRT's prostate cancer risk remains debated.

What did they get wrong (or right)?

Mostly right, but a few things deserve scrutiny. Including SHBG is appropriate since it determines how much testosterone is biologically active, and some men on TRT have high SHBG that blunts their response. That's not a commonly discussed point in short-form content, so credit where it's due.

The DHT mention is less clinically urgent than the creator implies. DHT rises on TRT, particularly with topical formulations, but routine DHT monitoring is not recommended in most clinical guidelines because the evidence linking TRT-driven DHT elevation to adverse outcomes is weak. Kaufman and Graydon (2004, Journal of the American Academy of Dermatology) noted hair loss associations, but monitoring DHT levels has limited actionability for most patients.

The creator's reference to their competitive career is the part that needs context. Monthly monitoring during what sounds like enhanced performance use is a different clinical scenario than standard TRT for hypogonadism. Applying that logic directly to typical TRT patients is a stretch. The risks, doses, and compounds involved are not equivalent, and presenting personal competitive-era experience as a transferable framework is misleading even if unintentionally so.

What should you actually know?

Here is what the evidence actually supports. Initial TRT monitoring at 30-60 days is reasonable for dose titration, though most formal guidelines anchor to 3 months. If your hematocrit climbs above 54%, that is a clinical red flag requiring action, not just observation. PSA should be checked at baseline and monitored, particularly in men over 40.

The panel the creator lists is legitimately comprehensive, but not everyone needs every marker at every interval. Liver enzyme elevation from injectable or oral testosterone is a real concern, though injectable testosterone cypionate or enanthate carries lower hepatotoxicity risk than oral 17-alpha-alkylated androgens. That distinction matters and the creator does not make it.

Prolactin monitoring is included, and this is worth explaining. Elevated prolactin on TRT can indicate a pituitary adenoma or other issue requiring further workup. It is a reasonable add to an initial panel, less necessary for routine maintenance unless symptoms arise.

Bottom line: find a provider who will actually review your results and adjust your protocol, not just sign off on a lab order. Monitoring without interpretation is just paperwork.